суббота, 27 августа 2011 г.

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.

Higher doses of the blood-thinner Plavix were no better at preventing sensitivity attacks, blood clots or expiration than the paradigm decrease amount in patients who had received artery-opening stents, supplemental inspection shows. The higher quantity - replicate the usual amount - was tested in patients with "high platelet reactivity," message they failed to answer to the drug at lower doses buy a good birkin istanbul. Plavix (clopidogrel) helps restrain clots from forming in patients who have sorry platelet reactivity and who have had stents inserted to lean open blocked arteries.

But the novel study "doesn't support" physicians using the higher, 150-milligram measure of Plavix after stenting, according to exploration lead author Dr Matthew Price, who presented the findings Tuesday at the annual joining of the American Heart Association in Chicago. So, the investigation leaves an impressive question unanswered: How to pay for heart patients who don't return well to Plavix? "It remains hesitating to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn buy aurogra 100. "It's an urgent writing-room to have done but the pitch issues are that a significant proportion of the patients remained with considerable platelet reactivity even after being on the higher dose".

Previous, smaller studies had indicated that Plavix might have more of an conclusion if the prescribe was doubled. "Platelet reactivity varies widely," distinguished Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a high-class reactivity position is associated with poorer outcomes after angioplasty and/or stenting. But until now, a high fly in the portion of Plavix "has not been tested in a charitable randomized clinical trial," he said.

For this trial, investigators tested a solid agglomeration of patients for platelet reactivity after they had undergone angioplasty to recall a drug-eluting stent. Drug-eluting stents give off medicines that employee ward off vessel re-closure. Over 2200 patients with momentous platelet reactivity were then randomized to meet 150 milligrams a day of Plavix or the requirement 75-milligram dose.

After six months, 2,3 percent of those winning either the higher or the debase dose suffered heart attacks, proficient blood clots in their stents, or died, the researchers report. Those irresistible the higher dispense of the blood-thinner didn't have any worse bleeding than those captivating the standard dose, indicating that the higher administer of Plavix in this group of patients wasn't any less safe. The consider was sponsored by Accumetrics, which makes VerifyNow, a try used to measure platelet function.

The makers of Plavix, Sanofi-Aventis and Bristol-Myers Squibb provided the drug, and intimation investigator Price also disclosed ties with pharmaceutical companies. "The shot does not brook a curing design of high dose clopidogrel in - patients with high-risk reactivity identified by a free platelet test," Price said. Still, Prasad said that higher danger determined populations may want to be studied before drawing any firm conclusions about dosing contraindicaciones de oxyelite pro. "Or perhaps we need a more influential drug," he said.

Комментариев нет:

Отправить комментарий